Epizyme, Inc. (EPZM)
(Delayed Data from NSDQ)
$12.10 USD
+0.19 (1.60%)
Updated May 3, 2019 04:00 PM ET
After-Market: $12.10 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$12.10 USD
+0.19 (1.60%)
Updated May 3, 2019 04:00 PM ET
After-Market: $12.10 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Puma (PBYI) Expands Study Cohort for Lead Candidate PB272
by Zacks Equity Research
Puma Biotechnology, Inc. (PBYI) has expanded the fourth cohort of the phase II SUMMIT study evaluating its lead candidate PB272 (neratinib) as a single agent in patients with solid tumors who have an activating HER2 mutation (basket study).
Alexion Blood Disorder Drug Gets Orphan Designation in U.S.
by Zacks Equity Research
Alexion (ALXN) announced that the FDA has granted orphan drug designation to ALXN1210 for the treatment of patients with paroxysmal nocturnal hemoglobinuria.
Vertex Pharma Issues Disappointing 2017 Orkambi Outlook
by Zacks Equity Research
Vertex Pharmaceuticals Incorporated (VRTX) announced preliminary financial results for 2016 and issued a financial outlook for 2017 on Jan 8, ahead of a Jan 9 presentation at the JP Morgan healthcare conference in San Francisco.